| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,060 | 3,080 | 23:01 | |
| 2,960 | 3,180 | 22:00 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.08. | Addex beschafft sich im Rahmen seines ATM-Vertrags 2,8 Millionen US-Dollar | 540 | Moneycab | Genf - Addex Therapeutics (SIX und Nasdaq: ADXN), ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich auf die Entwicklung eines Portfolios neuartiger kleinmolekularer allosterischer... ► Artikel lesen | |
| 26.08. | Addex Therapeutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 26.08. | Addex Therapeutics raises $2.8M via ATM offering, extending runway to Q4 2027 | 1 | Seeking Alpha | ||
| 26.08. | Addex nimmt mehrere Millionen US-Dollar über ATM-Vereinbarung ein | 9 | cash | ||
| ADDEX THERAPEUTICS SA ADR Aktie jetzt für 0€ handeln | |||||
| 26.08. | Addex Therapeutics: ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027 | 494 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, August 26, 2026
-
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 08.07. | Addex Therapeutics Ltd. - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| 08.07. | Addex Therapeutics: Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness | 529 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art.?53 LR
Geneva, Switzerland, July 8, 2026
-
Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 30.06. | Addex Therapeutics: Addex Shareholders Approve All Resolutions at Annual General Meeting | 491 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, June 30, 2026
-
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 25.06. | Addex Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript | 6 | Benzinga.com | ||
| 25.06. | Addex Therapeutics GAAP EPS of -CHF0.01 | 2 | Seeking Alpha | ||
| 25.06. | Addex Therapeutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 25.06. | Addex fällt im ersten Quartal tiefer ins Minus | 486 | Moneycab | Genf - Das Biotechunternehmen Addex hat im ersten Quartal des Geschäftsjahres 2026 einen etwas grösseren Verlust geschrieben. Die liquiden Mittel beliefen sich auf 0,9 Millionen Franken, nachdem es... ► Artikel lesen | |
| 25.06. | Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | 496 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, June 25, 2026
-
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 22.06. | Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026 | 442 | GlobeNewswire (Europe) | Geneva, Switzerland, June 22, 2026
-
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric... ► Artikel lesen | |
| 05.06. | Addex Therapeutics Ltd. - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| 05.06. | Addex Therapeutics: Addex Convenes Annual General Meeting 2026 | 445 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, June 5, 2026
-
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 15.05. | Addex Therapeutics Ltd. - 20-F, Annual and transition report of foreign private issuers | 20 | SEC Filings | ||
| 30.04. | Addex Therapeutics reports FY results | 22 | Seeking Alpha | ||
| 30.04. | Earnings Call Transkript: Addex Therapeutics H2 2026 offenbart strategische Neuausrichtung | 14 | Investing.com Deutsch | ||
| 30.04. | Addex Therapeutics Q4 2025 Earnings Call Transcript | 13 | Benzinga.com |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QUANTUM BIOPHARMA | 3,104 | +0,84 % | Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target | TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of... ► Artikel lesen | |
| JAGUAR HEALTH | 2,670 | -1,48 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.09.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 16.09.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.09.2026.ISIN NameAU0000090060 EUROPA... ► Artikel lesen | |
| LIPOCINE | 2,240 | +4,67 % | Lipocine Inc.: Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression | Study informed by encouraging exploratory efficacy findings and a favorable safety profile in the prior Phase 3 trial
Approximately 120 participants with severe... ► Artikel lesen | |
| THERAPEUTICSMD | 1,780 | -4,30 % | TherapeuticsMD, Inc. - 10-Q, Quarterly Report | ||
| ALLARITY THERAPEUTICS | 1,180 | -1,26 % | Allarity Therapeutics, Inc. - 8-K, Current Report | ||
| EXICURE | 1,020 | -5,56 % | EXICURE, INC. - 8-K, Current Report | ||
| COSMOS HEALTH | 0,297 | +3,70 % | Cosmos Health Inc.: Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June | 7.7 million contracted units added in under two weeks - Cana Laboratories' orderbook has grown from over 12 million units earlier this year to more than 32.7 million todaySecured orders for 1.04 million... ► Artikel lesen | |
| 60 DEGREES PHARMACEUTICALS | 0,980 | +2,29 % | 60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results | WASHINGTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne... ► Artikel lesen | |
| MEDICUS PHARMA | 0,171 | +0,41 % | Medicus Pharma Ltd: Medicus Pharma Announces Exclusive Development Focus for SkinJect in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment | PHILADELPHIA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and potentially... ► Artikel lesen | |
| SUNSHINE BIOPHARMA | 0,929 | +4,38 % | Sunshine Biopharma Inc.: Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies | Nanomolar potency against PLpro with broad-spectrum SARS-CoV-2 variants activitySignificant dose-dependent suppression of pulmonary viral replication in vivoStrong oral bioavailability and preferential... ► Artikel lesen | |
| CELLYAN BIOTECHNOLOGY | 0,121 | 0,00 % | Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period | HONG KONG, July 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply... ► Artikel lesen | |
| SHUTTLE PHARMACEUTICALS | 3,470 | +6,12 % | Shuttle Pharmaceuticals Holdings Inc.: United Dogecoin Purchases Dogecoin Miners and Secures Renewable Energy Data Centre Site | Gaithersburg, Maryland--(Newsfile Corp. - June 26, 2026) - United Dogecoin Inc. ("United Dogecoin" or the "Company"), a Dogecoin mining company driven by industry experts recently acquired by Shuttle... ► Artikel lesen | |
| BAYER | 49,030 | -1,94 % | Bayer, BASF und Allianz: Aktuelle Kursziele und eine Sonderchance | Bayer, BASF und Allianz gehören zu den prominentesten deutschen DAX-Konzernen und stehen derzeit erneut im Fokus der Anleger. Ein Blick auf die aktuellen Analysten-Kursziele zeigt, wie unterschiedlich... ► Artikel lesen | |
| MERCK KGAA | 132,60 | -1,22 % | Community-Rückblick: "Moderna wäre um min. 50% gestiegen, BioNTech bisher nicht mal 2%. That's it!" | © Foto: Julia Cebella - dpaNeue Onkologie-Daten sorgen bei BioNTech für Diskussionen: Warum reagiert die Aktie trotz guter Studienergebnisse kaum? Die wO User Diskutieren über Pipeline, Bewertung und... ► Artikel lesen | |
| NOVO NORDISK | 34,835 | -7,42 % | Pharma trifft KI: Anthropic an Bord: Novo will neue Wirkstoffe schneller entwickeln | © Foto: Christian Schultz/dpaNovo Nordisk will neue Medikamente schneller entwickeln und setzt dafür auf Anthropic. Die KI-Modelle sollen Forschung und Softwareentwicklung vorantreiben Enthaltene Werte:... ► Artikel lesen |